Adverum Biotechnologies, Inc. is a gene therapy company that develops treatment products for ocular and rare diseases, with a leading product candidate called ADVM-022. The ADVM-022 is a gene therapy treatment administered by a single intravitreal injection for patients with chronic retinal illnesses, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc has collaboration agreements with several institutions, including the University of California, and was established in 2006, with the headquarters located in Redwood City, California.